We expect significant growth in the area of Theranostics, our rapidly growing molecular radiotherapy service offers Lu177 Dotatate, Lu177 PMSA, Y90 SiRT, Ra223 Xofigo and I131 for benign and malignant disease and are actively beginning to look at working with P32 & Ho166. We work collaboratively with wider teams including on-site radiopharmacy. Our goal is to deliver the best service to our patients, both locally and within the wider Wessex region.